Cell News and Research

RSS

NCCN announces new guidelines for patients with pancreatic Cancer

The National Comprehensive Cancer Network (NCCN), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

30 Aug 2012

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most cases, the causes of the disorder are hard to determine, but some patients have been found to have genetic alterations leading to a shortening of their telomeres (the end regions of chromosomes that protect and stabilise DNA).

30 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Study shows molecular mechanism behind type 3c pancreatic diabetes

Mice develop pancreatic diabetes (type 3c) when they lack certain genes in the E2F group, and to understand how this happens, Olatz Zenarruzabeitia has focussed on the molecular mechanism behind it.

29 Aug 2012

New method simplifies pharmaceutical production of proteins

Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.

29 Aug 2012

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Johns Hopkins' Armstrong Institute for Patient Safety and Quality has received an $8.9 million grant from the Gordon and Betty Moore Foundation, the first award given as part of an ambitious new $500 million, 10-year program designed to eliminate all preventable harms that patients experience in the hospital.

29 Aug 2012

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

BMBF awards 16M€ to support German epigenome program initiative

The German Ministry for Research and Education (BMBF) will support the German epigenome program initiative "DEEP" with a budget of 16M€ over 5 years.

29 Aug 2012

Metabolism drives the brain clock, reveals study

The rhythm of life is driven by the cycles of day and night, and most organisms carry in their cells a common, (roughly) 24-hour beat. In animals, this rhythm emerges from a tiny brain structure called the suprachiasmatic nucleus (SCN) in the hypothalamus. Take it out of the brain and keep it alive in a lab dish and this "brain clock" will keep on ticking, ramping up or gearing down production of certain proteins at specific times of the day, day after day.

29 Aug 2012

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

29 Aug 2012

Scientists identify genes that underlie growth of primitive leukemia stem cells

University of Rochester Medical Center scientists believe they are the first to identify genes that underlie the growth of primitive leukemia stem cells, and then to use the new genetic signature to identify currently available drugs that selectively target the rogue cells.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Cyclin D3 protein regulates size and quantity of RBCs

The adult human circulatory system contains between 20 and 30 trillion red blood cells (RBCs), the precise size and number of which can vary from person to person. Some people may have fewer, but larger RBCs, while others may have a larger number of smaller RBCs. Although these differences in size and number may seem inconsequential, they raise an important question: Just what controls these characteristics of RBCs?

29 Aug 2012

SPR microscopy examines binding kinetics of membrane proteins

Proteins adorning the surfaces of human cells perform an array of essential functions, including cell signaling, communication and the transport of vital substances into and out of cells. They are critical targets for drug delivery and many proteins are now being identified as disease biomarkers - early warning beacons announcing the pre-symptomatic presence of cancers and other diseases.

29 Aug 2012

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Aeterna Zentaris Inc. today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia.

28 Aug 2012

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.

28 Aug 2012

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.

28 Aug 2012

ABCD4 and CblF proteins responsible for hereditary vitamin B12 deficiency

Vitamin B12 is vital for cell division, the synthesis of red blood cells and the functioning of the nervous system. Unable to produce the vitamin itself, the human body has to obtain it via animal proteins. So far it has been known that on its way into the cell vitamin B12 is absorbed by little organelles, so-called lysosomes. From there, the vitamin enters the cell interior with the aid of the transport protein CblF, which was discovered by the same research team three years ago.

28 Aug 2012

Cell News and Research

NCCN announces new guidelines for patients with pancreatic Cancer

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Study shows molecular mechanism behind type 3c pancreatic diabetes

New method simplifies pharmaceutical production of proteins

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

BMBF awards 16M€ to support German epigenome program initiative

Metabolism drives the brain clock, reveals study

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Scientists identify genes that underlie growth of primitive leukemia stem cells

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Cyclin D3 protein regulates size and quantity of RBCs

SPR microscopy examines binding kinetics of membrane proteins

Aeterna Zentaris commences enrollment in AEZS-130 Phase 2A trial for cancer cachexia

Herceptin® (trastuzumab) delivery methods: an interview with Dr Gustavo Ismael

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

ABCD4 and CblF proteins responsible for hereditary vitamin B12 deficiency

What are the challenges of cell line development? eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics